GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

British drugmaker GSK said on Wednesday its vaccine for respiratory syncytial virus (RSV) showed potential in a late-stage trial to help protect adults aged 50 to 59 years.

GSK's RSV vaccine shows positive results in adults aged 50-59

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.

GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?

Amgen

Biogen

Prothena

Vertex Pharmaceuticals

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

In the latest trading session, GSK (GSK) closed at $36.67, marking a +0.25% move from the previous day.

GSK (GSK) Ascends While Market Falls: Some Facts to Note

GSK PLC (LSE:GSK, NYSE:GSK) said its cancer immunotherapy drug, Jemperli (dostarlimab), has been recommended for approval by a key committee at the European Medicines Agency. Specifically, regulators have endorsed its use in combination with chemotherapy treatments to tackle primary advanced or recurrent endometrial cancer.

GSK cancer immunotherapy receives backing from key EMA committee

GSK PLC's (LSE:GSK, NYSE:GSK) latest out-of-court Zantac deal is important to the ongoing "overhang" over the investment case, Citigroup said. The US investment bank reiterated its belief that the FTSE 100 group will ultimately settle the entirety of the Zantac litigation "for $5bn or less" in the first quarter of 2024.

GSK settlement keeps it on course to remove Zantac overhang by early 2024, analyst says

In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.

Why GSK (GSK) Outpaced the Stock Market Today

The pharma giant settled four cases in California for an undisclosed amount to avoid the “distraction” of a trial.

GSK Settles Zantac Cases After Claims Popular Heartburn Drug Causes Cancer

GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to stop a high profile case concerning its heartburn drug Zantac heading to court in California. The FTSE 100-listed pharma giant said it had reached a confidential settlement in the Cantlay/Harper case over allegations Zantac caused cancer.

GSK strikes legal settlement over heartburn drug Zantac

GSK on Wednesday said it had reached a confidential settlement on a litigation in California over claims that the British drugmaker's heartburn drug Zantac caused cancer.

GSK reaches confidential settlement in California Zantac lawsuit

GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.

GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing

Ambev

Adyen NV

Bayer AG

British American Tobacco

Anheuser-Busch InBev

Diageo

FANUC Corp

Imperial Brands PLC

JD.com

Medtronic

Novozymes A/S

Omron Corp

Roche Holding AG

Safran SA

Shimano Inc

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The October 2023 Heat Map

GSK PLC (LSE:GSK, NYSE:GSK) has inked an exclusive three-year agreement, £2.5 billion with China's Zhifei to co-promote its shingles vaccine in China. With an option for extension, this strategic deal aims to significantly broaden the availability of Shingrix and accelerate patient access to the vaccine.

GSK inks £2.5bn shingles vaccine deal with China's Zhifei

GSK , on Monday, announced an exclusive partnership with China's Chongqing Zhifei Biological Products (Zhifei) for its shingles vaccine.

GSK signs shingles vaccine deal with China's Zhifei for about $3 bln

GSK PLC (LSE:GSK, NYSE:GSK) is set to restructure its research division, impacting scientists in the UK, the US, and Belgium, according to the Sunday Times. The pharmaceutical giant aims to replace its unified research unit with specialised teams focusing on three key areas: vaccines and infectious diseases, respiratory and immunology, and oncology.

GSK reportedly set to shake up R&D opertion

Pfizer

AstraZeneca

Merck

Moderna

CRISPR Therapeutics

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

Barclays

Burberry Group PLC

HSBC Holdings

Legal & General Group PLC

Lloyds Banking Group

National Grid

NatWest Group plc 

Rio Tinto plc Sponsored

Dividend yield is actually a fairly reliable indicator of value and future returns. There is an elevated risk of dividend cuts and suspensions when yields are so high, but in many cases, that seems unlikely. The UK does offer rich pickings to dividend investors.

Top 40 High-Yield Blue-Chip U.K. Stocks: Autumn 2023

Haleon PLC

GSK PLC (LSE:GSK, NYSE:GSK) has further reduced its stake in consumer health group Haleon PLC (LSE:HLN, NYSE:HLN), offloading 270 million shares for around £886 million. It is the second time in three months the drugs giant has lowered its holding in the maker of Sensodyne toothpaste and Panadol painkillers, raking in just under £1.9 billion in the process.

GSK banks almost £900m for Haleon stake sale

British drugmaker GSK on Friday said it raised 885.6 million pounds ($1.08 billion) from a stake sale in its spun-off consumer healthcare business Haleon at 328 pence a piece.

GSK raises 886 mln pounds from Haleon stake sale

GSK intends to sell a 2.9% stake, or about 270 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Thursday.

GSK to sell 2.9% stake in former consumer healthcare business Haleon

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announces plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit with GSK.

Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK

Britain's drugs regulator on Monday approved GSK's drug, Jemperli, to be used with chemotherapy for cancer of the womb lining as a first line treatment.

UK authorises GSK's drug to treat endometrial cancer

Apple

Amazon

Salesforce

Microsoft

Palantir Technologies

In the dynamic world of investing, there's always a buzz surrounding “smart money” stocks. This excitement isn't just about fleeting market trends; it's rooted in the savvy market decisions made by individuals with incredible financial acumen.

7 ‘Smart Money' Stocks Set to Explode Higher

GSK is a leading biopharmaceutical company with a focus on vaccines and products for major diseases. GSK's drug line-up is safe and profitable, with competitors facing larger sales loss exposure due to patent expirations. GSK has a strong balance sheet, high margins, and a sound revenue track record, making it a compelling value investment.

GSK: Strong Positioning And Trading At Historical Discount

News for GlaxoSmithKline Stock (GSK)